Oncolytics Biotech signs $25M share purchase agreement with Lincoln Park Capital Oncolytics Biotech has entered into a share purchase agreement with Lincoln Park Capital Fund that will provide an initial investment in Oncolytics of $1.0M and make available additional periodic investments of up to $25.0M over a 30-month term. Oncolytics received a $1.0M investment in exchange for the issuance of 600,962 common shares to LPC at a per share purchase price of $1.664. In addition, Oncolytics may sell up to $25.0M worth of common shares to LPC over the 30-month term.
News For ONCY From The Last 14 Days
Check below for free stories on ONCY the last two weeks.